- Home
- UNCY vs RPTX Comparison
UNCY vs RPTX Comparison
Compare UNCY & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- RPTX
- Stock Information
- Founded
- UNCY 2016
- RPTX 2016
- Country
- UNCY United States
- RPTX Canada
- Employees
- UNCY N/A
- RPTX N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- RPTX Health Care
- Exchange
- UNCY Nasdaq
- RPTX Nasdaq
- Market Cap
- UNCY 74.2M
- RPTX 78.2M
- IPO Year
- UNCY 2021
- RPTX 2020
- Fundamental
- Price
- UNCY $4.93
- RPTX $1.86
- Analyst Decision
- UNCY Strong Buy
- RPTX Strong Buy
- Analyst Count
- UNCY 5
- RPTX 3
- Target Price
- UNCY $55.20
- RPTX $4.50
- AVG Volume (30 Days)
- UNCY 419.1K
- RPTX 131.4K
- Earning Date
- UNCY 11-12-2025
- RPTX 11-06-2025
- Dividend Yield
- UNCY N/A
- RPTX N/A
- EPS Growth
- UNCY N/A
- RPTX N/A
- EPS
- UNCY N/A
- RPTX N/A
- Revenue
- UNCY N/A
- RPTX $250,000.00
- Revenue This Year
- UNCY N/A
- RPTX N/A
- Revenue Next Year
- UNCY $19,912.34
- RPTX N/A
- P/E Ratio
- UNCY N/A
- RPTX N/A
- Revenue Growth
- UNCY N/A
- RPTX N/A
- 52 Week Low
- UNCY $3.71
- RPTX $0.89
- 52 Week High
- UNCY $11.00
- RPTX $4.07
- Technical
- Relative Strength Index (RSI)
- UNCY 66.90
- RPTX 58.20
- Support Level
- UNCY $4.33
- RPTX $1.76
- Resistance Level
- UNCY $4.81
- RPTX $1.97
- Average True Range (ATR)
- UNCY 0.31
- RPTX 0.08
- MACD
- UNCY 0.04
- RPTX 0.00
- Stochastic Oscillator
- UNCY 70.07
- RPTX 57.38
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.